Frequently Asked Questions

The BrightKaire™  test is a simple blood test that helps clinicians choose the best antidepressant medication for patients . The test uses a combination of neuronal imaging, genetic, and clinical data to predict how well a patient will respond to different antidepressants and how likely they are to experience side effects. Each patient and their clinician receives a detailed report on how their brain is likely to respond to an assay of 18 antidepressants and various other medications.

‍

Preliminary results of BrightKaire's™ Pharmacogenetics test will be delivered to the ordering physician approximately 10-14 days from the time we receive the sample and order requisition form. Results for the final neuronal neuroplasticity score can take up to 8 weeks.

NeuroKaire™ (formerly Genetika+) is a HIPAA (Health Insurance Portability and Accountability Act) covered entity. Results that contain protected health information will only be shared with the ordering physician and as otherwise permitted by law.

Your patient’s identifiable health information collected through Neurokaire™ is protected in accordance with HIPAA requirements and kept confidential. De-identified data from Neurokaire™ is used to improve the way mental health is diagnosed and treated. De-identified data may be used in research and in the development of new drugs, therapies, and analytical tools. NeuroKaire's™ (formerly Genetika+) notice of privacy practices is available here.

NeuroKaire combines our knowledge and experience into a dynamic platform which can be used to advance drug discovery. From target discovery to post marketing, NeuroKaire can be applied throughout the drug development lifecycle. We operate in parallel with your non-clinical or clinical processes to provide actionable results such as mechanistic insight and patient stratification.

For biopharma partners who would like to speak to someone on our Biopharma Team or learn more about our portfolio for biopharma and research partners, please reach out to partnerships@neurokaire.com.

Neurokaire's BrightKaire test for depression is currently commercially available. We are CE and CLIA certified and fully operational in the USA, Europe and Israel. If you or someone you know is struggling to find the right antidepressant and would like to benefit from Brightkaire™ visit www.neurokaire.typeform.com/BrightKaire

To get started visit Our link

All of Neurokaire’s commercially available tests are run in CAP Accredited and CLIA Certified labs.

Clinicians considering prescribing antidepressants to their patients may utilize the BrightKaire™ blood test as a valuable tool to facilitate their decision-making process in finding the right drug for their patients.